Pharmacokinetics of acyclovir in adult horses

Journal of Veterinary Emergency and Critical Care

Volumn 15, Issue 3, 2005, Pages 174-178

  Wilkins, Pamela A ^a,c   Papich, Mark ^b   Sweeney III, Raymond W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Abortion; Central nervous system; Equine; Herpes; Respiratory

Indexed keywords

ANIMALIA; EQUIDAE; EQUINE HERPESVIRUS 1; EQUUS CABALLUS; HERPES; HERPES VIRUS TYPE 1; HUMAN HERPESVIRUS 1;

EID: 27744488497     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2005.00145.x     Document Type: Article

References (32)

1. Wilkins PA, Henninger R, Reed SW, et al. Acyclovir as treatment for EHV-1 myeloencephalopathy. Am Assoc Equine Pract Conf 2003;49:394-396.
2. Wilkins PA, Del Piero F, de Lahunta A, et al. Paralytic equine herpes virus: 1978-1997. Proceedings of the 8th International Conference on Equine Infection and Disease, Dubai, United Arab Emirates, 1998, pp. 596-597.
3. Del Piero F, Wilkins PA, DeLahunta A, et al. Fifteen cases of equine herpesvirus 1 (EHV-1) encephalomyelopathy in horses: pathologic and immunoperoxidase histochemical findings. Vet Pathol 1998; 35:441.
4. Edington N, Bridges GC, Patel JR. Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke. Arch Virol 1986; 90:111-124.
5. Patel JR, Edington N, Mumford JA. Variation in cellular tropism between isolates of equine herpesvirus-1 in foals. Arch Virol 1982; 74:41-51.
6. Campbell TM, Studdert MJ. Equine herpesvirus type 1 (EHV-1). Vet Bull 1983; 53:135-146.
7. Jackson TA, Osburn BI, Cordy DR, et al. Equine herpesvirus 1 infection of horses: studies on the experimentally induced neurologic disease. Am J Vet Res 1977; 38:709-719.
8. Del Piero F, Wilkins PA, Timoney PJ, et al. Fatal nonneurological EHV-1 infection in a yearling filly. Vet Pathol 2000; 37(6):672-676.
9. Perkins G, Ainsworth DM, Erb HN, et al. Clinical, hematological and biochemical findings in foals with neonatal equine herpes virus I infection compared with septic and premature foals. Equine Vet J 1999; 31 (5):422-426.
10. Mumford EL, Traub-Dargatz JL, Salman MD, et al. Monitoring and detection of acute viral respiratory tract disease in horses. J Am Vet Med Assoc 1998; 213(3):385-390.
11. Kohn CW, Fenner WR. Equine herpes myeloencephalopathy. Vet Clin N Am Equine Pract 1987; 3:405-419.
12. Donaldson MT, Sweeney CR. Herpesvirus myeloencephalopathy in horses: 11 cases (1982-1996). J Am Vet Med Assoc 1998; 213: 671-675.
13. Friday PA, Scarratt WK, Elvinger F, et al. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses. J Vet Intern Med 2000; 14:197-201.
14. Murray MJ, del Piero F, Jeffrey SC, et al. Neonatal equine herpesvirus type 1 infection on a thoroughbred breeding farm. J Vet Intern Med 1998; 12(1):36-41.
15. Wilkins PA. Acyclovir in the treatment of EHV-1 myeloencephalopathy. Proceedings of the 22nd American College of Veterinary Internal Medicine Forum, Minneapolis, MN, 2004, pp. 170-172.
16. Collins P. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J Antimicrob Chemother 1983; 12(Suppl. B):19-27.
17. Whitley RJ, Blum MR, Barton N, et al. Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. Am J Med 1982; 73(1A):165-771.
18. Van Dyke RB, Connor JD, Wyborny C, et al. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. Am J Med 1982; 73(1A):172-175.
19. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetics. J Pharmacokinet Biopharm 1978; 6:165-175.
20. Gibaldi M, Perrier P. Pharmacokinetics, 2nd edn. New York: Marcel Dekker Inc.; 1982, pp. 1-473.
21. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodymic Data Analysis: Concepts and Applications, 3rd edn. Stockholm: Apotekarsocieteten; 2001, 263pp.
22. Owens JG, Nasisse MP, Tadepalli SM, et al. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 1996; 19:488-490.
23. Krasney HC, de Miranda P, Blum MR, et al. Pharmacokinetics and bioavailability of acyclovir in the dog. J Pharmacol Exp Ther 1981; 216:281-288.
24. de Miranda P, Krasney HC, Page DA, et al. Species differences in the disposition of acyclovir. Am J Med 1982; 73:31-35.
25. de Miranda P, Whitley RJ, Blum MR, et al. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther 1979; 26:718-728.
26. Wagstaff AJ, Faulds D, Goa KL. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47(1):153-205.
27. Fletcher C, Bean B. Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm 1985; 19:518-524.
28. Mc Evoy G. ed. 8:18 antivirals, In: AHFS Drug Information, 40th edn. Bethesda, MD: American Society of Hospital-System Pharmacist; 1998, pp. 471-480.
29. Duffee NE, Chritensen JM, Craig AM. The pharmacokinetics of cefadroxil in the foal. J Vet Pharmacol Ther 1989; 12:322-326.
30. Rojanasthien N, Teekachunhatean S, Kumsorn B, et al. Bioequivalence study of generic acyclovir compared with the brand name acyclovir. J Med Assoc Thailand 2002; 85:1121-1129.
31. Al-Yamani MJ, Al-Khamis KI, El-Sayed YM, et al. Comparative bioavailability of two tablet formulations of acyclovir in healthy volunteers. Int J Clin Pharmacol Ther 1998; 36:222-226.
32. Standring-Cox R, Bacon TH, Howard BA. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. J Virol Methods 1996; 56:3-11.